ValoreQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSpese di vendita, generali e amministrative82.5 M87.8 M86.65 M86.62 M87.94 M349 MRicerca e sviluppo187.77 M165.77 M164.74 M216.21 M203.28 M750 MReddito operativo-122.28 M-142.94 M-107.89 M-170.89 M-113.28 M-535 MProventi non operativi, Totale5.94 M7.67 M7.93 M4.82 M5.58 M26 MOneri finanziari, al netto degli interessi capitalizzati——————Proventi non operativi, esclusi gli oneri finanziari9.55 M6.83 M5.79 M5.86 M6.51 M25 MEntrate/uscite straordinarie-3.61 M837 K2.14 M-1.04 M-934 K1 MUtile al lordo delle imposte-133.4 M-149.77 M-114 M-179.54 M-127.69 M-571 MQuota di utile——————Imposte-19 K1.31 M947 K873 K870 K4 MInteressi di minoranza——————Altri proventi/oneri al netto delle imposte-1.19 M1.25 M1.17 M273 K-693 K2 MUtile netto al lordo delle attività cessate-133.38 M-151.08 M-114.95 M-180.41 M-128.56 M-575 MAttività cessate——————Utile netto-133.38 M-151.08 M-114.95 M-180.41 M-128.56 M-575 MRegolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari-133.38 M-151.08 M-114.95 M-180.41 M-128.56 M-575 MUtile base per azione (EPS base)-1.34-1.57-1.17-1.81-1.28-5.83Utile diluito per azione (EPS diluito)-1.34-1.57-1.17-1.81-1.28-5.83Numero medio di azioni ordinarie in circolazione90.54 M96.29 M98.46 M99.77 M98.6 M393.12 MAzioni diluite in circolazione90.54 M96.29 M98.46 M99.77 M98.6 M393.12 MEBITDA-96.31 M-105.29 M-76.27 M-134.29 M-75.15 M-391 MEBIT-105.38 M-114.28 M-84.89 M-142.9 M-83.94 M-426 MCosto del fatturato——————Altri costi del venduto——————Ammortamento e svalutazione (liquidità)9.08 M8.99 M8.62 M8.61 M8.79 M35 M
Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA.